Indian Health Ministry Issues Advisory to States, UTs to Regulate Stem Cell Therapy; Limits Autism Application to Clinical Trials

September 20, 2026

ETV Bharat India

Overview

The Indian Ministry of Health and Family Welfare has issued a comprehensive advisory to all states and Union Territories, reinforcing regulations on stem cell therapies following directives from the Supreme Court. The advisory stipulates that stem cell treatments are permitted for routine clinical practice only for approved disease conditions, specifically limiting the therapeutic use of stem cells for Autism Spectrum Disorder (ASD) to approved clinical trials. This measure aims to prevent the commercial offering of unproven stem cell interventions and enhance patient safety and protection.

In Depth

Key Findings

The Indian Ministry of Health and Family Welfare has issued a stringent advisory to all states and Union Territories across India, mandating stricter regulation of stem cell therapies. This directive, spurred by a Supreme Court ruling, explicitly restricts the routine clinical application of stem cell therapies to only those disease conditions approved by the Ministry, with particular emphasis that stem cell interventions for Autism Spectrum Disorder (ASD) must be confined solely to approved clinical trials.

Technical and Clinical Details

The advisory is rooted in the National Guidelines for Stem Cell Research, first established in 2017. According to these guidelines, stem cell therapy can only be offered as a “standard treatment” if its scientific basis and clinical efficacy are firmly established, and if the specific disease condition is listed and approved by the Ministry of Health and Family Welfare. For all other conditions, particularly neurodevelopmental disorders like ASD, therapeutic use is permissible only within the framework of well-designed, ethically approved clinical trials until sufficient safety and efficacy are demonstrated. This measure is designed to combat the proliferation of unproven stem cell interventions being marketed as “commercial services,” thereby safeguarding patients from receiving ineffective or potentially harmful treatments and protecting them from significant financial and health risks. The advisory urges state and UT administrations to strictly adhere to and enforce these guidelines, promoting a responsible and evidence-based approach to regenerative medicine.

Background and Industry Context

Globally, while stem cell therapies hold immense promise for various intractable diseases, there has been a concerning rise in the unregulated and commercialized application of unproven treatments. In India, numerous clinics have offered expensive stem cell therapies for conditions such as ASD, often without robust scientific evidence, leading to significant exploitation and health risks for vulnerable patients and their families. The Supreme Court of India took cognizance of this issue, instructing the government to implement appropriate regulatory measures. This advisory is a direct response to that judicial mandate, aiming to protect public health and safety, and foster the ethical and scientific advancement of stem cell research and therapy. This move by India underscores a global trend toward stricter oversight in the regenerative medicine sector, reflecting similar concerns observed in both developed and emerging economies regarding patient protection and scientific integrity.

Strategic Significance and Outlook

The issuance of this advisory is expected to significantly reshape the landscape of stem cell therapy in India. Clinics and hospitals offering unapproved treatments are now subject to strict legal repercussions and increased scrutiny. Conversely, legitimate, evidence-based stem cell research and approved clinical trials will continue to be encouraged and supported. This regulatory clarity is anticipated to drive the development of truly effective and safe stem cell therapies, ultimately benefiting patients. India’s proactive stance on stem cell regulation may also influence international regulatory discussions, potentially accelerating similar efforts in other countries grappling with the ethical and scientific challenges of advanced regenerative treatments.

Source: https://www.etvbharat.com/en/health/stem-cell-therapy-regulation-in-india-advisory-enn26091704252

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.